Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

BACKGROUND: Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden. Ravulizumab administered every 8 weeks demonstrated noninferiority to eculizumab in two phase 3 trials. In regions...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Peipert, John Devin, Kulasekararaj, Austin G., Gaya, Anna, Langemeijer, Saskia M. C., Yount, Susan, Gonzalez-Fernandez, F. Ataulfo, Ojeda Gutierrez, Emilio, Martens, Christa, Sparling, Amy, Webster, Kimberly A., Cella, David, Tomazos, Ioannis, Ogawa, Masayo, Piatek, Caroline I., Wells, Richard, Sicre de Fontbrune, Flore, Röth, Alexander, Mitchell, Lindsay, Hill, Anita, Kaiser, Karen
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2020
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7473546/
https://ncbi.nlm.nih.gov/pubmed/32886668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0237497
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker